Antithrombin reduces inflammation and microcirculatory perfusion failure in closed soft-tissue injury and endotoxemia

Critical Care Medicine

Volumn 41, Issue 3, 2013, Pages 867-873

  Gierer, Philip ^a   Laue, Fabian ^a   Hoffmann, Johannes N ^b   Rotter, Robert ^a   Mittlmeier, Thomas ^a   Gradl, Georg ^a   Vollmar, Brigitte ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Antithrombin; Endotoxemia; Lipopolysaccharide; Microcirculation; Nicotinamide adenine dinucleotide fluorescence; Trauma

Indexed keywords

ANTITHROMBIN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; PENTOBARBITAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOFLUORESCENCE; CAPILLARY DENSITY; CELL INTERACTION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENDOTOXEMIA; EXTENSOR DIGITORUM LONGUS MUSCLE; FLUORESCENCE MICROSCOPY; HEMODYNAMICS; HISTOPATHOLOGY; HYPOXEMIA; INFLAMMATION; INFLAMMATORY CELL; LEUKOCYTE ADHERENCE; MALE; MICROCIRCULATION; MICROSURGERY; MUSCLE INJURY; MUSCLE PERFUSION; NONHUMAN; PRIORITY JOURNAL; RAT; SOFT TISSUE INJURY; TISSUE OXYGENATION;

ANIMALS; ANTITHROMBINS; BLOOD CELL COUNT; BLOOD COAGULATION; CELL DEATH; DISEASE MODELS, ANIMAL; ENDOTOXEMIA; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPOPOLYSACCHARIDES; MICROCIRCULATION; MICROSCOPY, FLUORESCENCE; RATS; RATS, SPRAGUE-DAWLEY; SOFT TISSUE INJURIES;

EID: 84874900463     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3182742d2c     Document Type: Article

References (32)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al.: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
2. Abraham E, Reinhart K, Svoboda P, et al.: Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29:2081-2089
3. Levi M, de Jonge E, van der Poll T: New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med 2004; 36:41-49
4. Rao LV, Nordfang O, Hoang AD, et al.: Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 1995; 85:121-129
5. Roemisch J, Gray E, Hoffmann JN, et al.: Antithrombin: A new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002; 13:657-670
6. Hoffmann JN, Fertmann JM, Jauch K W: Microcirculatory disorders in sepsis and transplantation: Therapy with natural coagulatory inhibitors antithrombin and activated protein C. Curr Opin Crit Care 2006; 12: 426-430
7. Oelschläger C, Römisch J, Staubitz A, et al.: Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood 2002; 99:4015-4020
8. Hoffmann JN, Vollmar B, Römisch J, et al.: Antithrombin effects on endotoxin-induced microcirculatory disorders are mediated mainly by its interaction with microvascular endothelium. Crit Care Med 2002; 30:218-225
9. Schaser KD, Vollmar B, Menger MD, et al.: In vivo analysis of microcirculation following closed soft-tissue injury. J Orthop Res 1999; 17: 678-685
10. Dixon CE, Clifton GL, Lighthall JW, et al: A controlled cortical impact model of traumatic brain injury in the rat. J Neurosci Methods 1991; 39:253-262
11. Lighthall JW, Dixon CE, Anderson T E: Experimental models of brain injury. J Neurotrauma 1989; 6:83-97
12. Tyml K, Budreau CH: A new preparation of rat extensor digitorum longus muscle for intravital investigation of the microcirculation. Int J Microcirc Clin Exp 1991; 10:335-343
13. Mittlmeier T, Vollmar B, Menger MD, et al.: Small volume hypertonic hydroxyethyl starch reduces acute microvascular dysfunction after closed soft-tissue trauma. J Bone Joint Surg Br 2003; 85:126-132
14. Gierer P, Mittlmeier T, Bordel R, et al.: Selective cyclooxygenase-2 inhibition reverses microcirculatory and inflammatory sequelae of closed softtissue trauma in an animal model. J Bone Joint Surg Am 2005; 87: 153-160
15. Kim D, Armenante PM, Durán W N: Transient analysis of macromolecular transport across microvascular wall and into interstitium. Am J Physiol 1993; 265(3 Pt 2):H993-H999
16. Vollmar B, Burkhardt M, Minor T, et al.: High-resolution microscopic determination of hepatic NADH fluorescence for in vivo monitoring of tissue oxygenation during hemorrhagic shock and resuscitation. Microvasc Res 1997; 54:164-173
17. Chance B, Cohen P, Jobsis F, et al.: Intracellular oxidation-reduction states in vivo. Science 1962; 137:499-508
18. Glanemann M, Vollmar B, Nussler AK, et al.: Ischemic preconditioning protects from hepatic ischemia/reperfusion-injury by preservation of microcirculation and mitochondrial redox-state. J Hepatol 2003; 38:59-66
19. Mizutani A, Okajima K, Uchiba M, et al.: Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 2003; 101: 3029-3036
20. Murakami K, McGuire R, Cox RA, et al.: Recombinant antithrombin attenuates pulmonary inflammation following smoke inhalation and pneumonia in sheep. Crit Care Med 2003; 31:577-583
21. Sorg H, Hoffmann JN, Menger MD, et al.: Antithrombin is as effective as heparin and hirudin to prevent formation of microvascular thrombosis in a murine model. Thromb Haemost 2006; 96:371-377
22. Sorg H, Hoffmann JN, Rumbaut RE, et al.: Efficacy of antithrombin in the prevention of microvascular thrombosis during endotoxemia: An intravital microscopic study. Thromb Res 2007; 121:241-248
23. Kaneider NC, Reinisch CM, Dunzendorfer S, et al.: Syndecan-4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes. J Cell Sci 2002; 115(Pt 1):227-236
24. Eisele B, Lamy M, Thijs LG, et al.: Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998; 24:663-672
25. Warren BL, Eid A, Singer P, et al.: Caring for the critically ill patient. Highdose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286:1869-1878
26. Dellinger RP, Levy MM, Carlet JM, et al.: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
27. Kienast J, Juers M, Wiedermann CJ, et al.: Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006; 4:90-97
28. Gierer P, Hoffmann JN, Mahr F, et al.: Sublethal trauma model with systemic endotoxemia for the study of microcirculatory disorders after the second hit. J Surg Res 2008; 147:68-74
29. Ince C, Coremans JM, Bruining H A: In vivo NADH fluorescence. Adv Exp Med Biol 1992; 317:277-296
30. De Backer D, Donadello K, Taccone FS, et al.: Microcirculatory alterations: Potential mechanisms and implications for therapy. Ann Intensive Care 2011; 1:27
31. Marechal X, Favory R, Joulin O, et al.: Endothelial glycocalyx damage during endotoxemia coincides with microcirculatory dysfunction and vascular oxidative stress. Shock 2008; 29:572-576
32. Tsen A, Kirschenbaum LA, LaRow C, et al.: The effect of anticoagulants and the role of thrombin on neutrophil-endothelial cell interactions in septic shock. Shock 2009; 31:120-124